Introduction
Now is a time when the value of new opportunities may be highest
as technology valuations may be at their lowest due to current financial
market conditions, but the window wont last! Risk is higher as short
term exit routes are less realisable. Money invested has to work
harder and be more efficient. Risks have to be analysed deeper and
existing investments re-structured to fit the new economy.
The consequence of this is that the contractual costs of doing
business will escalate.
P2F can help reduce these costs by being retained on a short to
medium term basis and in certain cases providing some work in return
for carried interest in equity or delivery of key business development
income milestones, such as securing an early licensee.
Simon Youlton has a track record in early life science ventures
that includes being a Director on a management buy-out team of a
life science co; advising on strategic and operational plans for
a number of academic spin out ventures including:
Serving on the Boards of spin out ventures (Spear, PETRRA) and
working with bus dev teams from a number of successful CRUK spin
outs including KuDOS and Antisoma.
In addition through P2F’s BIOnetwork we
can source and recruit scientific experts from across the many biomedical
scientific disciplines to help conduct due diligence.
As well as a business development network, Simon has built up a
network of scientific knowledge and contacts at Europe’s most
prestigious medical research centres having managed CRT’s
business relationships with such foreign non-CRUK institutes for
more than 6 years. These include the Netherlands Cancer Institute,
The Deutsches Krebsforchungszentrum (the German Cancer Research
Center); IFOM/IEO in Italy, the Danish Cancer Centre, PRBB and CRG
Barcelona, University of Barcelona, and numerous other Universities
across Europe. Simon also did the ground work for setting up the
first trans-Atlantic business for CRT and the groundwork to setting
up the CRT Inc Boston office.
P2F also routinely promotes new seedcorn investment opportunities
arising from academia and works with young companies already funded
in a business development capacity that may have synergies with
your existing portfolio companies.
We would be interested in hearing from any investors to ascertain
the type of new projects they are seeking or opportunities to help
leverage value from their existing portfolio assets.
|
